Suprascapular Nerve Block for Shoulder Pain in the First Year After Stroke

A Randomized Controlled Trial

Zoe Adey-Wakeling, BMBS; Maria Crotty, PhD; E. Michael Shanahan, PhD

Background and Purpose—Shoulder pain is a common complication after stroke that can impede participation in rehabilitation and has been associated with poorer outcomes. Evidence-based treatments for hemiplegic shoulder pain are limited. Suprascapular nerve block (SSNB) is a safe and effective treatment of shoulder pain associated with arthritic shoulder conditions, but its usefulness in a stroke population is unclear.

Methods—We undertook a randomized controlled trial assessing the effectiveness of SSNB in a population of 64 stroke patients (onset < 1 year) with hemiplegic shoulder pain. The primary outcome was pain measured on a visual analogue scale (VAS). Secondary outcomes were disability (Modified Rankin Scale, Croft Disability Index) and quality of life (EuroQol Health Questionnaire). All participants were assessed before randomization, and at 1, 4, and 12 weeks postintervention. Both groups continued with routine therapy.

Results—Although both intervention and control groups demonstrated reduction in pain score, participants who received SSNB consistently demonstrated superior, statistically significant pain reduction compared with placebo. Mean VAS reduction in the SSNB group was >18 mm greater than participants receiving placebo injection. The number needed to treat with SSNB to reduce 1 stroke survivor’s pain by 50% at 4 weeks is 4. No significant differences in function or quality of life were observed. No adverse events were reported.

Conclusions—Suprascapular nerve block is a safe and effective treatment for patients with hemiplegic shoulder pain.

Clinical Trial Registration—URL: http://www.anzctr.org.au. Unique identifier: ACTRN12609000621213.

Key Words: hemiplegia • nerve block • shoulder pain • stroke

Shoulder pain is a distressing complication of hemiplegia1 and is 1 of the 4 most commonly reported medical complications of stroke.2 The cause of hemiplegic shoulder pain is multifactorial,1,4 and contributions have been described from biomechanical changes,1,5 spasticity,6,7 and central-pain mechanisms.8,9 Population based studies suggest that approximately one quarter of stroke survivors develop hemiplegic shoulder pain,10,11 although higher rates of 52% to 54% have been reported in large studies using retrospective,12 prospective,13 and literature review14 methodologies. Hemiplegic shoulder pain is associated with reduced functional ability,15 a higher incidence of depression,15 interference with rehabilitation, and an increased length of hospitalisation.16 Despite the high incidence and significant impact of shoulder pain post stroke, there is little robust evidence to inform clinical practice.17,18 with reviews examining the management of hemiplegic shoulder pain concluding that further efforts are required to examine intervention options.1,17,18

Published systematic reviews have not included information on the use of suprascapular nerve block (SSNB) as an intervention type because of the emerging nature of this procedure in stroke populations and a lack of robust trials. Since commencement of this trial, 2 small trials have been published in this field.19,20 Comparison of SSNB with intra-articular steroid injection20 did not demonstrate either treatment to be superior, although in a preliminary study19 of 10 people, comparison of SSNB with ultrasound treatment trended toward greater improvement in the SSNB group. Conclusions regarding the efficacy of SSNB are unable to be drawn from these studies because of small numbers, absence of power analysis, and absence of placebo control.

Suprascapular nerve block has been shown to be a safe21 and efficacious treatment for shoulder pain associated with rheumatoid arthritis and degenerative shoulder conditions.22-24 It is unclear whether the results of these trials can be generalized to people with nonarthritic shoulder pain. The objective of our study was to compare the effect of SSNB to placebo on
shoulder pain in a population of stroke survivors in the first year after stroke. The secondary objective was to examine the effects on function and quality of life.

Methods
The study design is a parallel group, randomized, placebo-controlled trial. Sixty-four participants gave written informed consent and were randomly assigned to an experimental group (suprascapular nerve block or placebo group) or an experimental group with normal saline injection. A protocol article was published at commencement.23

Setting
Participants were recruited from acute stroke and rehabilitation wards across Adelaide, South Australia, between 2009 and 2012. Ethics approval was granted for all sites, including Repatriation General Hospital, Flinders Medical Center, The Queen Elizabeth Hospital, Hampstead Rehabilitation Center, Griffith Rehabilitation Hospital, and Calvary Rehabilitation Hospital. Participants were recruited after education sessions and provision of brochures to each facility.

Participants and Eligibility Criteria
Participants were required to be aged >18 years with a diagnosis of acute stroke within the previous 12 months, and to report hemiplegic shoulder pain with a minimum VAS of 30 mm (100-mm scale). Minimum pain score was selected in the clinical context that invasive interventions are not routine for mild pain. Exclusion criteria included significant cognitive impairment (Mini-Mental State Examination < 23) or language deficits (inability to follow 2-stage command, limited English) that might affect the reliability of responses to outcome measure scales. Hypersensitivity to injection agents excluded participants. After protocol publication and trial commencement, authors decided to exclude palliative patients, because it was deemed unethical to knowingly offer placebo during palliation.

Randomization, Treatment Allocation, and Blinding
A computer-generated randomized number sequence allocated participants to either the intervention or the control group. Randomization was managed by a Clinical Trials Pharmacist external to the study. Allocation was assigned after baseline assessment. The principal investigator (Z.A.) was responsible for eligibility assessment, consent, baseline assessment, and injection of all participants. Where she was involved in treating the participant, consent was obtained by another investigator. All outcome assessments were completed by 1 physiotherapist who was masked to treatment allocation. Participants and treating staff remained masked to allocation.

Interventions
Participants were randomly assigned to receive either a SSNB or a placebo subcutaneous normal saline injection. The principal investigator (Z.A.) was responsible for syringe preparation and was aware of the allocation as the injection technique and appearance of syringe contents varied between groups. Both groups continued to receive routine therapy. Syringe size and needle gauge (10 mL syringe and 21-gauge 38-mm needle) were consistent across both groups. Blinding of participants was maintained by consistent preparation and positioning of all patients, and all received a 2-mL subcutaneous infiltration of 1% lidocaine before injection.

The experimental group received a suprascapular nerve block injection with 1 mL of 40 mg/mL methylprednisolone and 10 mL 0.5% bupivacaine hydrochloride. The technique used for SSNB has been used in a previous trial.22 Anatomic landmarks were used to determine injection site into the supraspinous fossa (see the online-only Data Supplement). The needle was introduced parallel to the scapular blade and the syringe contents slowly injected into the enclosed space of the supraspinous fossa. The placebo group received an injection of 5 mL normal saline infiltrated subcutaneously to the same region of the shoulder.

Outcomes
Participants were assessed before randomization and at 1, 4, and 12 weeks after injection. Demographic data collected included age, sex, dominance, duration since stroke, stroke type, and location. The primary outcome of pain was measured using a vertical Visual Analogue Scale (VAS). This measure involves a 100-mm vertical line anchored with the extremes of subjective pain. Self-perceived pain severity is rated and recorded in millimeter readings.26 The VAS is easy to use, readily reproducible,27 validated in a stroke population,28 and commonly used in previous research. A minimum VAS change of 20 mm is reportedly required to achieve clinically significant pain reduction for patients with initial pain scores >60 mm.26 Secondary outcomes of disability and quality of life were measured using the Modified Rankin Scale,29 Croft Disability Questionnaire,30 and the EuroQol Health Questionnaire.31 The Croft Disability Questionnaire includes 22 questions regarding disability associated with shoulder pain. This validated measure was chosen because of applicability in a more dependent population. The minimal level of detectable change (90% confidence) is defined as 3 points.

Sample Size and Statistical Analysis
A prospective sample size calculation, previously described in the protocol article,23 calculated that a sample size of 26 participants per group was required to achieve a statistically and clinically significant difference between the 2 groups (power 80%, α 0.05). Minimally significant clinical change in VAS was set at 20 mm. Allowing for an attrition rate of 20% to accommodate deaths and withdrawals, we aimed to recruit a total of 66 participants, 33 per group.

Research into the efficacy of SSNB in shoulder pain associated with rheumatoid arthritis demonstrated a mean VAS difference of 22.9 mm at 1 week, with the intervention superior to placebo. This study was used to assist in the development of the power calculation, with the hypothesis that treatment with SSNB would reduce hemiplegic shoulder pain by the minimally important clinical change of 20 mm when compared with placebo injection.

All data entry was completed by a research assistant masked to allocation. Data were exported into IBM SPSS (version 20) for statistical analyses on an intention to treat basis. Independent samples t-tests, Mann–Whitney U tests, and χ2 test of association were used to compare groups at baseline. Repeated measures were analyzed using a generalized linear mixed model because of the advantage in dealing with missing values (maximum likelihood analysis) and the robust approach to calculation of effect. Results of primary outcomes are expressed as means with 95% confidence intervals. The level for statistical significance for hypothesis tests was set at 0.05. Linear regression analysis was performed to assess potential associations in responding patients. EuroQol Health Questionnaire weights were derived using the Australian general population algorithm.34

Results
Of 129 persons assessed for eligibility, 64 were enrolled and randomized into 2 groups (Figure 1). Reasons for exclusion are tabulated in the online-only Data Supplement. The mean time from stroke onset to trial referral was 12 weeks; 11 (SD, 8) weeks for control group and 13 (SD, 9) weeks for intervention group. The mean difference between scheduled and actual follow-up was <1 day for all time points.

Three participants in the control group were lost to follow-up. Another control participant was not available for follow-up at 4 weeks, but was available at subsequent time points. One participant from the control group and 3 from the intervention group were unable to be contacted at 12 weeks. A total of 29 participants in the intervention group and 28 in the control group completed the trial with an overall attrition rate of 11%.
The demographic characteristics of participants at baseline were similar across groups (Table 1). The groups were well matched on stroke severity (National Institutes of Health Stroke Scale), motor weakness of the affected upper limb, and pain severity (VAS). Percentages of infarct versus hemorrhage were comparable, and Oxfordshire stroke classification demonstrated equivalent numbers of anterior and posterior circulation strokes. Potentially confounding factors such as spasticity and subluxation were also similar. No sex-based differences were detected.

**Primary Outcomes**

Results for the primary outcome of pain (VAS) are summarized in Table 2 and Figure 2. Mean pain scores at baseline were comparable across the groups ($P=0.379$). Pairwise contrasts between groups were statistically significant at all follow-up time points, with the SSNB group consistently demonstrating greater mean VAS reduction when compared with placebo ($P=0.02$ at week 1, $P=0.01$ at week 4, $P=0.02$ at week 12). Linear regression analyses were performed to assess associations and predictors of responders. There were no statistically significant associations between any of the variables assessed; namely age, sex, spasticity (Modified Ashworth Scale), stroke severity (baseline National Institutes of Health Stroke Scale) or disability (Croft Disability Index).

**Secondary Outcomes**

There were no differences between groups at any follow-up time point in the secondary outcomes of disability and quality of life which were assessed with Modified Rankin Scale, Croft Disability Scale, and EuroQol Health Questionnaire. Both the intervention and control groups recorded a mean Modified Rankin Scale score of 4 (SD, 1) at baseline. The majority of participants in both groups had a Modified Rankin Scale score of 3 or 4 (moderate – moderately severe disability) at all time points. The mean change in Croft Disability Index was non-significant between groups and at each follow-up time point. EuroQol Health Questionnaire weights for both groups reflected improved health-related quality of life over time, independent of effect from group allocation. No adverse effects were reported.
Table 1. Baseline Characteristics of Participants With Hemiplegic Shoulder Pain

<table>
<thead>
<tr>
<th>Baseline Variable</th>
<th>Control (n=32)</th>
<th>Intervention (n=32)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, y</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–65</td>
<td>16 (50%)</td>
<td>15 (46.9%)</td>
</tr>
<tr>
<td>66–79</td>
<td>13 (40.6%)</td>
<td>19 (28.1%)</td>
</tr>
<tr>
<td>80+</td>
<td>3 (9.4%)</td>
<td>8 (25%)</td>
</tr>
<tr>
<td>Male, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>15 (46.9%)</td>
<td>21 (65.6%)</td>
</tr>
<tr>
<td>Right hemisphere stroke, n (%)</td>
<td>21 (65.6%)</td>
<td>23 (71.9%)</td>
</tr>
<tr>
<td>Right hand dominant, n (%)</td>
<td>26 (81.3%)</td>
<td>29 (90.6%)</td>
</tr>
<tr>
<td>Duration poststroke, mean weeks (SD)</td>
<td>11 (8)</td>
<td>13 (8)</td>
</tr>
<tr>
<td>NIHSS, mean (SD)</td>
<td>29 (90.6%)</td>
<td>27 (84.1%)</td>
</tr>
<tr>
<td>Motor score† affected arm</td>
<td>2 (1)</td>
<td>2 (1)</td>
</tr>
<tr>
<td>Stroke type</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infarct, n (%)</td>
<td>3 (9.4%)</td>
<td>5 (15.6%)</td>
</tr>
<tr>
<td>Hemorrhage, n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oxfordshire classification</td>
<td>10 (31.3%)</td>
<td>6 (18.8%)</td>
</tr>
<tr>
<td>TACS</td>
<td>16 (50.0%)</td>
<td>21 (65.6%)</td>
</tr>
<tr>
<td>PACS</td>
<td>4 (12.5%)</td>
<td>2 (6.3%)</td>
</tr>
<tr>
<td>POCI</td>
<td>1 (3.1%)</td>
<td>2 (6.3%)</td>
</tr>
<tr>
<td>Other</td>
<td>1 (3.1%)</td>
<td>1 (3.1%)</td>
</tr>
<tr>
<td>With subluxation, n (%)</td>
<td>10 (31.3%)</td>
<td>10 (31.3%)</td>
</tr>
<tr>
<td>Modified Rankin Scale, mean (SD)</td>
<td>4 (1)</td>
<td>4 (1)</td>
</tr>
<tr>
<td>Croft Disability Q, mean (SD)</td>
<td>12 (5)</td>
<td>12 (4)</td>
</tr>
<tr>
<td>Modified Ashworth Scale</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>16 (50%)</td>
<td>16 (50%)</td>
</tr>
<tr>
<td>1</td>
<td>11 (34.4%)</td>
<td>11 (34.4%)</td>
</tr>
<tr>
<td>2</td>
<td>5 (15.6%)</td>
<td>2 (6.5%)</td>
</tr>
<tr>
<td>3</td>
<td>0 (0%)</td>
<td>2 (6.5%)</td>
</tr>
</tbody>
</table>

Values are number (%) unless otherwise stated. LACS indicates lacunar syndrome; NIHSS, National Institute of Health Stroke Scale; PACS, partial anterior circulation syndrome; POCI, posterior circulation syndrome; and TACS, total anterior circulation syndrome.

*NIHSS total score 5–15 = moderate severity stroke.
†NIHSS motor score upper limb of 2 = some effort against gravity, limb cannot get to or be maintained at 90°.

**Discussion**

Comparable clinically important variables at baseline reflected successful randomization. Although there was a higher proportion of total anterior circulation strokes in the control group, the composite of total and partial anterior syndromes was evenly distributed (81.3% in control group, 84.4% in intervention group). It is possible that subjective pain report in participants with total anterior circulation strokes may have been influenced by higher cortical dysfunction, though the authors accounted for this in exclusion criteria. Although the difference of 4.12 mm in baseline VAS between groups did not reach clinical or statistical significance, it could indicate a potential confounding factor. The mean time between stroke onset and enrollment was similar between groups, in keeping with the typical nadir of hemiplegic shoulder pain at the 2- to 3-month mark. A single SSNB injection provides superior reduction in hemiplegic shoulder pain in comparison with placebo injection. The SSNB group demonstrated a mean VAS reduction of ≥37 mm, with an 18-mm difference between intervention and control groups, maintained at each assessment. The definition of a minimal clinically important change on the 100-mm VAS has been debated; articles report clinical importance from as little as 12 to 15 mm, up to 30 mm. In our pretrial protocol we aimed for a VAS change of 20 mm to reach a robust level of clinical importance. To consider our results in a clinically relevant context, data were subsequently reviewed to assess the percentage of responders who achieved criteria for patient-defined successful pain reduction of 50% and 30 mm. The 4-week time point was taken to be of highest clinical interest, given the known pharmacodynamics of the active injection agent. At 4 weeks, 78% of all participants receiving SSNB reported any improvement in symptoms, with 80% of these responders demonstrating ≥20-mm VAS pain reduction. The number needed to treat with SSNB to achieve a clinically significant pain reduction of 50% in 1 person was 4 (95% confidence interval [CI], 3–29) at 4 weeks and 4 at 12 weeks (95% CI, 2–25).

The marked placebo response (mean change of 25 mm) is expected in a subjective outcome trial using a sham injection, and is consistent with other studies of SSNB. A degradation of this effect over follow-up might have been expected, and we hypothesize that the maintained placebo response over time may reflect the natural history of hemiplegic shoulder pain as compared with degenerative shoulder conditions.

Despite significant pain reduction, there was no impact on the secondary outcomes of function and quality of life. The self-reporting of health-related quality of life after stroke is affected by multiple factors, and improvement in a single variable of pain was insufficient to improve overall quality of life. Pain reduction may allow for more intensive therapies which could impact future independence.

Suprascapular nerve block is not a new intervention. There has been an increasing body of literature in nonstroke populations, describing the SSNB as a simple, successful, and reproducible intervention. As evidenced by results of this trial, the breadth of application of this intervention continues to expand. The suprascapular nerve involves a high proportion

Table 2. VAS Pain Scores Between Groups by Treatment Allocation

<table>
<thead>
<tr>
<th>Time Point</th>
<th>Control Mean (95% CI)</th>
<th>Intervention Mean (95% CI)</th>
<th>Pairwise Contrast Control-Intervention</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline</td>
<td>73.03 (66.10–79.99)</td>
<td>68.91 (62.25–75.56)</td>
<td>0.01</td>
<td>0.379</td>
</tr>
<tr>
<td>1 wk</td>
<td>47.90 (36.58–58.21)</td>
<td>29.78 (19.29–40.23)</td>
<td>18.12</td>
<td>0.02*</td>
</tr>
<tr>
<td>4 wk</td>
<td>49.73 (40.62–58.83)</td>
<td>31.69 (21.40–41.97)</td>
<td>18.04</td>
<td>0.01*</td>
</tr>
<tr>
<td>12 wk</td>
<td>46.20 (34.63–57.78)</td>
<td>28.14 (17.81–38.46)</td>
<td>18.06</td>
<td>0.02*</td>
</tr>
</tbody>
</table>

Sequential Bonferroni adjusted significance level is 0.05. Confidence interval bounds are approximate.

*Statistically significant.
of sympathetic fibres, and supplies 70% of pain fibres to the shoulder. The mechanism of initial pain reduction is attributed to blocking these sensory fibers and reducing nociceptive input to the central nervous system. Lack of degradation of treatment effect by 3 months suggests an additional potential mechanism in this population. It has been postulated that there may be a reduction in central sensitisation secondary to diminished nociceptive stimulus as a potential effect of SSNB. This is in keeping with more recent studies, which have identified features consistent with somatosensory sensitisation in patients with HSP, suggesting both nociceptive and neuropathic components of pain.

**Strengths and Limitations**

This is the first randomized controlled study to investigate SSNB as a treatment for hemiplegic shoulder pain. We recruited from stroke and rehabilitation settings across the city and think our findings are generalizable to clinical practice. A single injector and single outcome assessor throughout this study reduced the risk of variations in technique and assessments. In future studies, alternatives to the Croft Disability Index could be considered. In practice, this questionnaire did not clearly delineate between disability secondary to hemiplegia and limitations secondary to pain.

The major limitation of this trial is that it is a small study with a comparatively short follow-up period of 3 months. Estimation of treatment effect may be greater in this current study given the influence of a smaller sample size. Further work is required with larger sample size, with the aim of identifying characteristics of clinical responders and clarifying the mechanism of therapy effect in this population.

**Conclusions**

SSNB is a safe and effective treatment option for patients with hemiplegic shoulder pain in the first year after stroke. The intervention is easily reproducible in the clinical setting, offering a practical and important advance for this patient population.

**Acknowledgments**

We thank Kelly Pinkney for outcome assessment, Maayken van den Berg for data analysis and statistical analysis, and Pawel Skuza for statistical advice.

**Sources of Funding**

This study was supported by a grant from Foundation Daw Park, Research Management Committee, Repatriation General Hospital.

**Disclosures**

None.

**References**


Suprascapular Nerve Block for Shoulder Pain in the First Year After Stroke: A Randomized Controlled Trial
Zoe Adey-Wakeling, Maria Crotty and E. Michael Shanahan

Stroke. 2013;44:3136-3141; originally published online August 22, 2013;
doi: 10.1161/STROKEAHA.113.002471
Stroke is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2013 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/44/11/3136

Data Supplement (unedited) at:
http://stroke.ahajournals.org/content/suppl/2013/08/22/STROKEAHA.113.002471.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Stroke can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Stroke is online at:
http://stroke.ahajournals.org//subscriptions/
SUPPLEMENTAL MATERIAL

Supplemental Table:

Supplemental Table I: Reasons for Non-Enrolment

Supplemental Figure:

Supplemental Figure I: Anatomical landmarks for suprascapular nerve block injection
### Supplemental Table I: Reasons for Non-Enrolment

<table>
<thead>
<tr>
<th>Excluded from Randomisation (n=65)</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Did not meet Eligibility Criteria (n=42)</th>
</tr>
</thead>
<tbody>
<tr>
<td>VAS &lt; 3/10</td>
</tr>
<tr>
<td>Insufficient Cognition / Language</td>
</tr>
<tr>
<td>Pain in Other Region</td>
</tr>
<tr>
<td>Palliative Patient</td>
</tr>
<tr>
<td>Stroke &gt; 12 months ago</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Declined to Participate (n=18)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Unwilling for Randomisation to Placebo</td>
</tr>
<tr>
<td>Needle Phobia</td>
</tr>
<tr>
<td>No reason given</td>
</tr>
<tr>
<td>Risk of adverse reaction</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Referred but Unable to be Contacted (n=5)</th>
</tr>
</thead>
</table>


Supplemental Figure I: Anatomical landmarks for suprascapular nerve block injection